Most people taking Wegovy lose around 14% of their body weight over about 72 weeks. For someone starting at 250 pounds, that translates to roughly 35 pounds. Results vary significantly from person to person, with some losing considerably more and others less, but clinical trials consistently show meaningful weight loss for the majority of participants.
Average Weight Loss in Clinical Trials
In the large-scale clinical trials used to approve Wegovy, adults taking the 2.4 mg maintenance dose lost an average of about 14% of their starting body weight over 68 to 72 weeks. Participants in these trials also followed a reduced-calorie diet and increased their physical activity, so the results reflect the combination of medication plus lifestyle changes, not the drug alone.
To put that percentage in real-world terms:
- Starting weight of 200 lbs: roughly 28 pounds lost
- Starting weight of 250 lbs: roughly 35 pounds lost
- Starting weight of 300 lbs: roughly 42 pounds lost
People in the placebo groups, who made the same diet and exercise changes without the medication, typically lost around 2 to 3% of their body weight. So the drug itself accounts for most of the difference.
How Quickly the Weight Comes Off
Weight loss with Wegovy doesn’t happen all at once. The medication follows a gradual dosing schedule designed to reduce side effects, particularly nausea. You start at a low dose of 0.25 mg per week and increase every four weeks: 0.5 mg, then 1 mg, then 1.7 mg, before reaching the full maintenance dose at week 17. That means you spend roughly four months just ramping up.
During the early titration phase, weight loss is modest. Most of the significant loss happens after you reach the maintenance dose. In trial data, weight continued to decline steadily through about week 60, then began to plateau. So the bulk of results take 12 to 16 months to fully materialize. If you’ve been on Wegovy for only two or three months and feel underwhelmed, that’s expected.
Some people can’t tolerate the 2.4 mg dose due to gastrointestinal side effects. In those cases, 1.7 mg is an approved maintenance option. Trial modeling shows the 1.7 mg dose still provides meaningful weight loss across key measures, though the higher dose offers incremental additional benefit.
Not Everyone Loses the Same Amount
The 14% average is just that: an average. Individual responses to Wegovy span a wide range. In clinical trials, a substantial proportion of participants lost 10%, 15%, or even 20% or more of their body weight. At the same time, a smaller group lost less than 5%. Researchers don’t fully understand why some people respond dramatically while others see more modest results, but factors like genetics, metabolic health, starting weight, adherence, and lifestyle habits all play a role.
People with type 2 diabetes tend to lose less weight on GLP-1 medications compared to those without diabetes. This is a consistent finding across studies of this drug class, not unique to Wegovy. If you have diabetes, a result closer to 7 to 10% body weight loss is more typical, which is still clinically significant for improving blood sugar, blood pressure, and cardiovascular risk.
How Wegovy Compares to Zepbound
Zepbound (tirzepatide) is the other major injectable weight loss medication, and many people want to know how the two stack up. A head-to-head study showed participants taking Zepbound 10 mg or 15 mg lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% for those on Wegovy. That’s a meaningful gap.
However, a higher-dose formulation of Wegovy (7.2 mg) is in development and has shown weight loss of about 21%, putting it on par with Zepbound’s higher doses. This formulation isn’t yet widely available, but it narrows the gap considerably for people who respond well to semaglutide and prefer to stay on it.
Both medications work by mimicking gut hormones that regulate appetite and fullness. Zepbound targets two hormone pathways while Wegovy targets one, which likely explains the difference at currently approved doses. The choice between them often comes down to insurance coverage, availability, side effect tolerance, and cost rather than efficacy alone.
What Happens After You Stop
One of the most important things to understand about Wegovy is that weight regain after stopping is common. Studies tracking participants after discontinuation show that most people regain a significant portion of their lost weight within a year. This doesn’t mean the medication “didn’t work.” It means obesity is a chronic condition, and the biological drivers of weight gain, including increased hunger signals and metabolic adaptation, return when the medication is removed.
Most prescribers now treat Wegovy as a long-term or indefinite medication, similar to how blood pressure drugs manage hypertension rather than cure it. If you’re considering Wegovy, it’s worth thinking of it as an ongoing commitment rather than a short-term fix.
Factors That Affect Your Results
Clinical trial participants weren’t just taking a weekly injection. They also reduced their calorie intake and aimed to increase physical activity. While the medication does the heavy lifting by reducing appetite and slowing digestion, the lifestyle component matters. People who combine Wegovy with consistent dietary changes and regular movement tend to land on the higher end of outcomes.
Other practical factors that influence results include how consistently you take the injection (missing doses reduces effectiveness), whether you’re on other medications that promote weight gain, your sleep quality, and stress levels. Starting weight also matters in absolute terms: someone at a higher starting weight will typically lose more total pounds even if the percentage is similar.
Setting realistic expectations helps. If you lose 10 to 15% of your body weight over a year, that falls squarely within the range seen in major trials and is enough to produce measurable improvements in blood pressure, cholesterol, joint pain, sleep apnea, and overall quality of life.